Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-11
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 5 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 10 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-11 | ||||||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-12 | ||||||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-31 | ||||||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-11 | ||||||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-12 | ||||||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-31 | ||||||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-05 | ||||||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-12 | ||||||
| 2023-12-31 | 0.00% 10-K · filed 2025-02-27 | ||||||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-28 | ||||||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-30 | ||||||
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-14 | ||||||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-16 | ||||||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-14 | ||||||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-14 | ||||||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-19 | ||||||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-16 | ||||||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-15 | ||||||
| 2018-12-31 | 0.00% 10-K · filed 2020-03-25 | ||||||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-14 | ||||||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-15 | ||||||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-29 | ||||||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-14 | ||||||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-14 | ||||||
| 2016-09-30 | 0.00% 10-Q · filed 2016-11-10 | ||||||
| 2016-06-30 | 0.00% 10-Q · filed 2016-08-15 | ||||||
| 2015-12-31 | 0.00% 10-K · filed 2016-03-30 | ||||||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-10 | ||||||
| 2014-12-31 | 0.00% 10-K · filed 2015-03-12 | ||||||
| 2014-06-30 | 0.00% 10-Q · filed 2014-08-07 | ||||||
| 2014-03-31 | 0.00% 10-Q · filed 2014-05-08 | ||||||
| 2013-12-31 | 0.00% 10-K · filed 2014-03-13 | ||||||
| 2013-10-28 | 0.00% 10-K · filed 2016-03-30 | 0.00% 10-K · filed 2014-03-13 | |||||
| 2013-09-30 | 0.00% 10-Q · filed 2013-11-12 | ||||||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-07 | ||||||
| 2013-06-03 | 0.00% 10-K · filed 2016-03-30 | ||||||
| 2013-03-31 | 0.00% 10-Q · filed 2014-05-08 | ||||||
| 2012-12-31 | 0.00% 10-K · filed 2014-03-13 | ||||||
| 2012-06-30 | 0.00% 10-Q · filed 2012-08-14 | ||||||
| 2011-12-31 | 0.00% 10-K · filed 2014-03-13 | ||||||
| 2011-06-30 | 0.00% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |